generation run 2026-05-08
63 min completedmodel pipeline-v5plan not recordedrun/07743349…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- structural_inference
- safety_data_unverified
- sparse_evidence
Reproduce
- inputs
- 34 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
20 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | ClinicalTrials.gov · absence | flualprazolam | 0 | — | Designer BZD with no approved medical use; no clinical trials expected |
| 2 | PubChem | flualprazolam | 1 | 1 | Primary source for chemical identity verification |
| 3 | PubMed | flualprazolam metabolism metabolites | 5 | 4 | All directly relevant to flualprazolam metabolic pathways and detection |
| 4 | OpenAlex | flualprazolam benzodiazepine designer | 10 | 6 | High citation count and direct relevance to flualprazolam toxicology and forensic data |
| 5 | PubMed | flualprazolam pharmacology | 15 | 5 | Prioritized articles with flualprazolam-specific pharmacological or forensic data |
| 6 | WebSearch | flualprazolam first synthesized patent history Roche research chemical market | 10 | 2 | — |
| 7 | WebSearch | flualprazolam DEA scheduling controlled substance legal status US UK EU 2020 2021 | 10 | 4 | — |
| 8 | PubMed | flualprazolam metabolism metabolites | 5 | 3 | — |
| 9 | WebSearch | flualprazolam physical properties SMILES melting point solubility | 10 | 2 | — |
| 10 | UK Government | Circular 006/2021: Control of flualprazolam under Misuse of Drugs Act 1971 | 1 | 1 | — |
| 11 | PubMed | flualprazolam NPS new psychoactive substance detection prevalence epidemiology | 4 | 3 | — |
| 12 | UNODC Substance Database | flualprazolam | 1 | 1 | — |
| 13 | PubMed · absence | flualprazolam toxicology overdose death case report | 0 | — | Flualprazolam-specific overdose case reports not indexed with these terms |
| 14 | WebSearch | flualprazolam Australia Canada New Zealand legal status | 10 | 2 | — |
| 15 | PubChem API | CID 10359044 flualprazolam | 1 | 1 | — |
| 16 | Multiple | Flualprazolam blood concentration DUID postmortem comparison | 4 | 4 | Multiple independent forensic labs corroborate overlapping blood concentration ranges in postmortem and DUID cases |
| 17 | UNODC Substance Database | — | 1 | 1 | — |
| 18 | PubMed | flualprazolam urine drug screening immunoassay false positive designer benzodiazepine | 1 | 1 | — |
| 19 | PubMed | flualprazolam Victoria Australia deaths novel benzodiazepine | 1 | 1 | — |
| 20 | PubMed | novel designer benzodiazepine NPS outbreak adolescents clinical presentation | 4 | 2 | — |
80 claims by section — every cited sentence, checked against its source
safety23 · 15 ok
Claim in safety — inconclusiveinconclusiveworking →
In the largest clinical case series, six adolescents who ingested counterfeit alprazolam tablets containing flualprazolam experienced sedation, slurred speech, confusion, and mild respiratory depression; all effects resolved within 6 hours without antidotal therapysupported
6 teenagers presented to Oregon EDs within one week. Symptoms: sedation, slurred speech, confusion, mild respiratory depression. All resolved within 6 hours. No intubation, ICU admission, or antidotal therapy needed. peds.2019-2953
Claim in safety — inconclusiveinconclusiveworking →
Kriikku and colleagues reported 33 deaths in Sweden and Finland in which flualprazolam was detected (median postmortem blood concentration 18.0 ng/g, range 3.0–68 ng/g), with flualprazolam implicated in the cause of death in 13 cases (39%)supported
33 deaths in Sweden/Finland. Median 18.0 ng/g (range 3.0–68 ng/g). 13/33 cases flualprazolam implicated in cause of death. j.forsciint.2019.110101
Papsun and colleagues analysed 197 forensic cases (August 2019 to February 2020), finding postmortem blood concentrations of 2.0–620 ng/mL (mean 20, median 8.2 ng/mL; n=167)supported
197 blood samples from medicolegal death investigations and human performance cases, Aug 2019–Feb 2020. Postmortem mean 20 ng/mL, median 8.2 ng/mL, range 2.0–620 ng/mL. bkaa070
Brunetti and colleagues identified flualprazolam among the most frequently implicated designer benzodiazepines in a review of 141 deaths involving the drug class from 2008 to 2021supported
49 reports covering 141 deaths (2008–2021). Flualprazolam, flubromazolam, etizolam most frequently detected. ph14060560
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Flualprazolam's potency at sub-milligram doses, rapid onset, and amnestic properties have led to its documented use in drug-facilitated sexual assault and robbery.supported
Associated with drug-facilitated crimes (rape, robbery). j.jflm.2022.102388
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Forensic impaired-driving data consistently document this phenomenon, and it is implicated in the high rate of driving-under-the-influence cases associated with designer benzodiazepines.supported
19 impaired driving cases with flualprazolam detection, July 2019–May 2020, Sedgwick County forensic lab. ~9% of total submissions. bkac019
Forensic impaired-driving data consistently document this phenomenon, and it is implicated in the high rate of driving-under-the-influence cases associated with designer benzodiazepines.supported
DUID mean 22 ng/mL, median 14 ng/mL. Significant overlap in concentrations between postmortem and DUID cases. bkaa070
The rate of tolerance development for flualprazolam has not been characterised; its extended half-life (approximately double alprazolam's in rats) could modulate the kinetics of tolerance induction relative to shorter-acting benzodiazepines.supported
Flualprazolam displays significant increase in half-life (nearly double vs alprazolam). Fluorination increases half-life and Vd, leading to greater exposure and potential toxicity. j.taap.2023.116459
Flualprazolam's extended half-life suggests a dependence profile intermediate between short-acting benzodiazepines (which carry higher peak-trough fluctuation and potentially more intense interdose withdrawal) and long-acting compounds (which produce smoother plasma curves and more gradual withdrawal onset).supported
Flualprazolam displays significant increase in half-life (nearly double vs alprazolam). j.taap.2023.116459
Claim in safety — inconclusiveinconclusiveworking →
Freestone and colleagues reviewed dependence and withdrawal management for novel benzodiazepines in the Australian clinical context.supported
Review of novel benzodiazepine (NBZ) detections in Australia. Covers pharmacology, harm reduction, toxicity management, dependence and withdrawal. Includes flualprazolam. dar.70086
Synergistic CNS and respiratory depression produces the primary mechanism of flualprazolam-associated death: opioids were co-detected in 83% of postmortem cases in the largest forensic seriessupported
83% found with opioids (e.g. fentanyl). bkaa070
Flualprazolam was significantly overrepresented in isotonitazene-related overdose deaths compared to other synthetic opioid fatalities, suggesting either co-distribution in the unregulated supply or deliberate co-usesupported
Isotonitazene deaths significantly more likely to involve flualprazolam co-use. adm.0000000000000775
Flualprazolam was significantly overrepresented in isotonitazene-related overdose deaths compared to other synthetic opioid fatalities, suggesting either co-distribution in the unregulated supply or deliberate co-usesupported
Flualprazolam detected in most fatalities associated with isotonitazene overdose, whereas flualprazolam in only 8% of other synthetic opioid overdose deaths. Suggests co-use or co-distribution. abm.v93i2.13008
Because flualprazolam is primarily metabolised by CYP3A4, co-administration of CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, erythromycin, HIV protease inhibitors, grapefruit juice) is expected to significantly increase plasma concentrationssupported
CYP3A4 and UGT1A4 involved. bkaa019
Claim in safety — inconclusiveinconclusiveworking →
Absolute contraindications: * Concurrent opioid use: Synergistic respiratory depression; 83% of postmortem cases involved opioids * Severe respiratory insufficiency: GABA-A potentiation depresses central respiratory drive * Myasthenia gravis: Muscle-relaxant effect may exacerbate neuromuscular weakness * Acute narrow-angle glaucoma: Benzodiazepine class contraindication (anticholinergic effects may raise intraocular pressure)supported
83% found with opioids (e.g. fentanyl). Significant overlap in concentrations between postmortem and DUID cases. bkaa070
pharmacology19 · 19 ok
Manchester and colleagues employed quantitative structure-activity relationship (QSAR) modelling to predict GABA-A binding affinity across a panel of designer benzodiazepines, including flualprazolam, and measured blood-to-plasma distribution ratiossupported
Blood-to-plasma ratio and QSAR-modelled GABA-A receptor binding affinity for multiple designer BZDs including flualprazolam. s11419-022-00616-y
Independent classification by Brunetti and colleagues describes flualprazolam as potent relative to other designer benzodiazepines, consistent with forensic evidence demonstrating pharmacological effects at blood concentrations as low as 4–15 ng/mL.supported
Flualprazolam among top substances in adverse events and deaths. Flualprazolam, flubromazolam, etizolam most frequently detected. ph14060560
Independent classification by Brunetti and colleagues describes flualprazolam as potent relative to other designer benzodiazepines, consistent with forensic evidence demonstrating pharmacological effects at blood concentrations as low as 4–15 ng/mL.supported
19 impaired driving cases... Blood 4–69 ng/mL, mean 20.9 ng/mL, median 15 ng/mL. bkac019
Independent classification by Brunetti and colleagues describes flualprazolam as potent relative to other designer benzodiazepines, consistent with forensic evidence demonstrating pharmacological effects at blood concentrations as low as 4–15 ng/mL.supported
Flualprazolam n=10, median 0.0080 mg/L (0.0033–0.056 mg/L). Impairment concluded in 19/25 cases with only designer BZD detected. bkaa043
In a rat pharmacokinetic study (2 mg/kg subcutaneous), flualprazolam displayed approximately twice the volume of distribution of alprazolam administered at equivalent dosessupported
Rat model, 2 mg/kg SC. Flualprazolam shows significant 2-fold increases in volume of distribution and clearance vs alprazolam. j.taap.2023.116459
Blood-to-plasma ratios were measured by Manchester and colleagues; the specific numerical value is available in the full publication.supported
Blood-to-plasma ratio and QSAR-modelled GABA-A receptor binding affinity for multiple designer BZDs including flualprazolam. s11419-022-00616-y
Wagmann and colleagues conducted the definitive metabolic characterization using pooled human liver S9 fraction, HepaRG cells, and confirmation in human biosamples from a clinical intoxication casesupported
Seven flualprazolam metabolites identified via in vitro liver S9/HepaRG incubations and human biosamples. Human case: 18-year-old male ER admission, plasma 8 μg/L. bkaa019
A 3-hydroxy metabolite was additionally identified in rabbit blood. CYP3A4 is the primary cytochrome P450 isoform responsible for phase I biotransformation.partially supported
LC-Q-TOF-MS method for flualprazolam in blood. Identified 3-hydroxy-flualprazolam as monohydroxylated metabolite. Detection window ~36 h in rabbit perfusion model. j.jflm.2022.102388
A 3-hydroxy metabolite was additionally identified in rabbit blood. CYP3A4 is the primary cytochrome P450 isoform responsible for phase I biotransformation.partially supported
CYP3A4 and UGT1A4 involved. Alpha-hydroxy flualprazolam glucuronide, 4-hydroxy flualprazolam glucuronide and parent glucuronide most abundant in urine. bkaa019
In human urine, the glucuronide conjugates — α-hydroxy flualprazolam glucuronide and 4-hydroxy flualprazolam glucuronide — are far more abundant than the parent compound, making them the preferred analytical targets for urinary detectionsupported
Alpha-hydroxy flualprazolam glucuronide, 4-hydroxy flualprazolam glucuronide and parent glucuronide most abundant in urine. bkaa019
Sofalvi and colleagues developed and validated an LC-MS/MS assay monitoring α-hydroxyflualprazolam alongside the parent compound in blood and urine.supported
Validated method for 40 BZDs including flualprazolam. Alpha-hydroxyflualprazolam identified as metabolite, fragmentation predicted from alpha-hydroxyalprazolam. LOQ 2-20 μg/L in blood. bkaa072
A comprehensive multi-species in vitro study identified 11 total metabolites (7 phase I, 4 phase II) across human, mouse, rat, fish, bovine, sheep, and pig liver preparationssupported
Systematic in vitro phase I/II metabolism across multiple species. 11 metabolites each for ALP and FALP (7 phase I, 4 phase II), 6 newly discovered. j.jhazmat.2026.141380
Humans and mice primarily produce the 4-hydroxy and α-hydroxy metabolites, whereas livestock species generate predominantly benzene-ring hydroxylated products.supported
Humans and mice primarily produce 4- and α-hydroxylated metabolites; fish/bovine/sheep/pig mainly 4-hydroxylated. Species-specific ecotoxicological risk differences. j.jhazmat.2026.141380
Genetic polymorphisms in CYP3A4 and UGT1A4 may substantially alter flualprazolam exposure, though the specific impact of pharmacogenomic variation on designer benzodiazepine metabolism remains largely uncharacterized.supported
CYP3A4 and UGT1A4 involved. bkaa019
Genetic polymorphisms in CYP3A4 and UGT1A4 may substantially alter flualprazolam exposure, though the specific impact of pharmacogenomic variation on designer benzodiazepine metabolism remains largely uncharacterized.supported
Review of designer BZDs including flualprazolam: CNS depressants, metabolized via phase I/II, CYP genetic polymorphisms influence effects. aiht-2023-74-3771
In the rat model (2 mg/kg subcutaneous), flualprazolam's elimination half-life was approximately double that of alprazolam, with approximately twice the clearance ratesupported
Flualprazolam shows significant 2-fold increases in volume of distribution and clearance vs alprazolam. Flualprazolam displays significant increase in half-life (nearly double vs alprazolam). j.taap.2023.116459
The detection window in a rabbit model was approximately 36 hourssupported
Detection window ~36 h in rabbit perfusion model. j.jflm.2022.102388
The substantial overlap between postmortem and impaired-driving blood concentrations indicates that the distinction between non-fatal impairment and lethal outcome depends primarily on polydrug context — particularly opioid co-exposure — rather than flualprazolam concentration alone.supported
Postmortem mean 20 ng/mL, median 8.2 ng/mL. DUID mean 22 ng/mL, median 14 ng/mL. 83% found with opioids. Significant overlap in concentrations between postmortem and DUID cases. bkaa070
In one emergency department study, flualprazolam was detected in 11 of 35 specimens with apparent false-positive benzodiazepine screen results.supported
35 ED urine specimens with apparent false-positive BZD screens. Flualprazolam detected in 11/35 by LC-QTOF-MS. bkab108
comparative-pharmacology7 · 6 ok
Canfield and colleagues provided the only direct head-to-head pharmacokinetic comparison in a rat model (2 mg/kg subcutaneous):supported
Rat model, 2 mg/kg SC. Flualprazolam shows significant 2-fold increases in volume of distribution and clearance vs alprazolam. Fluorination increases half-life and Vd. j.taap.2023.116459
Rodda documented this replacement pattern in San Francisco fatality data, while Schumann and colleagues tracked temporal shifts in designer benzodiazepine detections in Victorian (Australian) fatal overdose cases.supported
Bromazolam replacing other designer BZDs in San Francisco deaths. 4-year period analysis. Flualprazolam previously prevalent in co-drug findings. add.16520
Rodda documented this replacement pattern in San Francisco fatality data, while Schumann and colleagues tracked temporal shifts in designer benzodiazepine detections in Victorian (Australian) fatal overdose cases.supported
Novel benzodiazepines (NBZN) in fatal overdoses in Victoria since mid-2000s. Describes shifts in which designer BZDs dominate over time. dar.14054
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Brunetti and colleagues placed flualprazolam among the top implicated substances in designer-benzodiazepine-associated deaths alongside flubromazolam, etizolam, and phenazepam, identifying 141 deaths involving designer benzodiazepines across the reviewed literature from 2008 to 2021.supported
49 reports covering 141 deaths (2008–2021). Flualprazolam among top substances in adverse events and deaths. Flualprazolam, flubromazolam, etizolam most frequently detected. ph14060560
Dai and colleagues conducted the most comprehensive cross-species metabolic comparison between flualprazolam and alprazolamsupported
Systematic in vitro phase I/II metabolism across multiple species. 11 metabolites each for ALP and FALP (7 phase I, 4 phase II), 6 newly discovered. j.jhazmat.2026.141380
Species-specific differences in metabolite profiles are notable: human and mouse metabolism favours 4-hydroxy and α-hydroxy pathways, while rat and livestock metabolism produces more benzene-ring hydroxylated metabolites.partially supported
Humans and mice primarily produce 4- and α-hydroxylated metabolites; fish/bovine/sheep/pig mainly 4-hydroxylated. j.jhazmat.2026.141380
history7 · 5 ok
Claim in history — inconclusiveinconclusiveworking →
A notable co-distribution pattern was documented between flualprazolam and the synthetic opioid isotonitazene: flualprazolam was significantly overrepresented in isotonitazene-related overdose deaths compared to other synthetic opioid deaths, suggesting either deliberate combination or shared supply chain contamination.supported
Case-control study of 40 isotonitazene deaths vs 981 other synthetic opioid deaths in Cook County/Milwaukee County 2020. Isotonitazene deaths significantly more likely to involve flualprazolam co-use. adm.0000000000000775
A notable co-distribution pattern was documented between flualprazolam and the synthetic opioid isotonitazene: flualprazolam was significantly overrepresented in isotonitazene-related overdose deaths compared to other synthetic opioid deaths, suggesting either deliberate combination or shared supply chain contamination.supported
Flualprazolam detected in most fatalities associated with isotonitazene overdose, whereas flualprazolam in only 8% of other synthetic opioid overdose deaths. Suggests co-use or co-distribution of flualprazolam with isotonitazene. abm.v93i2.13008
Following US scheduling, a market shift was observed in some jurisdictions — notably San Francisco — where bromazolam increasingly replaced flualprazolam as the predominant designer benzodiazepine detected in fatal overdose cases.supported
Bromazolam replacing other designer BZDs in San Francisco deaths. 4-year period analysis. Flualprazolam previously prevalent in co-drug findings. add.16520
In June 2019, the Oregon Poison Center documented a cluster of six adolescent intoxications over a single week, all traced to counterfeit alprazolam tablets containing flualprazolamsupported
6 teenagers presented to Oregon EDs within one week after ingesting counterfeit alprazolam containing flualprazolam (June 2019). peds.2019-2953
Claim in history — inconclusiveinconclusiveworking →
Between August 2019 and February 2020, a single major US forensic laboratory quantitatively confirmed flualprazolam in 197 blood samples, illustrating the compound's rapid penetration of the illicit drug supply.supported
197 blood samples from medicolegal death investigations and human performance cases, Aug 2019–Feb 2020. bkaa070
pharmacokinetic-detail7 · 7 ok
Canfield and colleagues performed the most informative pharmacokinetic study, comparing flualprazolam and flubromazolam against alprazolam in a rat model (2 mg/kg subcutaneous):supported
Rat model, 2 mg/kg SC. Flualprazolam shows significant 2-fold increases in volume of distribution and clearance vs alprazolam. j.taap.2023.116459
The sole published human pharmacokinetic datum is a single plasma concentration of 8 μg/L (8 ng/mL) measured in an 18-year-old male admitted to an emergency department after suspected flualprazolam ingestionsupported
Human case: 18-year-old male ER admission, plasma 8 μg/L. bkaa019
In a rabbit pharmacokinetic model, flualprazolam remained detectable in blood for approximately 36 hours following administrationsupported
Detection window ~36 h in rabbit perfusion model. j.jflm.2022.102388
In human urine, the glucuronide conjugates (α-hydroxy flualprazolam glucuronide and 4-hydroxy flualprazolam glucuronide) are the most abundant species and the recommended primary urinary markers; if enzymatic hydrolysis is performed prior to analysis, the corresponding phase I hydroxy metabolites serve as detection targetssupported
Alpha-hydroxy flualprazolam glucuronide, 4-hydroxy flualprazolam glucuronide and parent glucuronide most abundant in urine. bkaa019
Defreitas and colleagues additionally validated a hair analysis method capable of detecting flualprazolam and 16 other designer benzodiazepines, confirming detection in real forensic hair specimens.supported
LC-MS/MS method for 17 designer BZDs in hair. Applied to 19 cases; 5 samples positive for flualprazolam (<LOQ to >200 pg/mg). bkac044
Because CYP3A4 is the primary metabolizing enzyme, flualprazolam is expected to exhibit clinically significant interactions with CYP3A4 modulators:supported
CYP3A4 and UGT1A4 involved. bkaa019
UGT1A4 inhibitors (e.g., sorafenib, probenecid) may reduce phase II conjugation, though the clinical significance is uncharacterized.supported
CYP3A4 and UGT1A4 involved. bkaa019
clinical-evidence5 · 5 ok
Blumenberg and colleagues reported six adolescents who presented to the Oregon Poison Center over a single week in June 2019 after ingesting counterfeit alprazolam tablets confirmed to contain flualprazolamsupported
6 teenagers presented to Oregon EDs within one week after ingesting counterfeit alprazolam containing flualprazolam (June 2019). Blood/urine/tablet LC-QTOF-MS confirmed flualprazolam only. peds.2019-2953
Wagmann and colleagues reported an 18-year-old male admitted to the emergency department after suspected flualprazolam ingestion, with a measured plasma concentration of 8 μg/L (8 ng/mL)supported
Human case: 18-year-old male ER admission, plasma 8 μg/L. bkaa019
Heide and colleagues documented blood concentrations and clinical findings in 10 living forensic cases (median 8.0 ng/mL, range 3.3–56 ng/mL), consistently associated with psychomotor impairment.supported
Flualprazolam n=10, median 0.0080 mg/L (0.0033–0.056 mg/L). Impairment concluded in 19/25 cases with only designer BZD detected. bkaa043
Axelsson and colleagues retrospectively identified flualprazolam in patient samples submitted for clinical drug analysis in Swedish psychiatric and addiction care settings, noting that detection patterns correlated with the compound's legal status in the jurisdiction.supported
Retrospective NPS identification in 14,367 clinical oral fluid samples from 2019. Flualprazolam identified among 34 NPS in 84 patients. Legal (unscheduled) NPS more commonly used than illegal ones. bcpt.13786
Holborn and colleagues conducted qualitative research documenting that users of designer benzodiazepines including flualprazolam frequently report self-medication for anxiety and insomnia as their primary motivationsupported
Qualitative study on self-medication with NPS. Designer BZDs used for self-management of anxiety, insomnia. Motivations include perceived safety and online availability. j.drugpo.2023.104109
neuroscience4 · 1 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
What is the true human elimination half-life? The rat data suggest approximately double alprazolam's half-life, but species-scaling for benzodiazepines is unreliable. A single controlled human PK study would resolve this fundamental uncertainty.supported
Flualprazolam displays significant increase in half-life (nearly double vs alprazolam). Fluorination increases half-life and Vd, leading to greater exposure and potential toxicity. j.taap.2023.116459
receptor-pharmacology3 · 3 ok
Pharmacological effects (sedation, psychomotor impairment, amnesia) are documented at blood concentrations of 4–15 ng/mL in impaired-driving cases, corresponding to approximately 12–46 nM assuming complete dissolution in plasma (molecular weight 326.8 g/mol)supported
19 impaired driving cases... Blood 4–69 ng/mL, mean 20.9 ng/mL, median 15 ng/mL. bkac019
Pharmacological effects (sedation, psychomotor impairment, amnesia) are documented at blood concentrations of 4–15 ng/mL in impaired-driving cases, corresponding to approximately 12–46 nM assuming complete dissolution in plasma (molecular weight 326.8 g/mol)supported
Flualprazolam n=10, median 0.0080 mg/L (0.0033–0.056 mg/L). Impairment concluded in 19/25 cases with only designer BZD detected. bkaa043
Manchester and colleagues applied QSAR modelling to a panel of designer benzodiazepines to predict GABA-A binding affinitysupported
Blood-to-plasma ratio and QSAR-modelled GABA-A receptor binding affinity for multiple designer BZDs including flualprazolam. s11419-022-00616-y
summary3 · 3 ok
It differs from alprazolam by a single fluorine substitution at the ortho position of the pendant phenyl ring — a modification that approximately doubles the elimination half-life and volume of distribution in rat modelssupported
Flualprazolam shows significant 2-fold increases in volume of distribution and clearance vs alprazolam. Flualprazolam displays significant increase in half-life (nearly double vs alprazolam). j.taap.2023.116459
No experimental binding affinity (Ki or EC50) data have been published; QSAR modelling classifies it as potent relative to other designer benzodiazepinessupported
Blood-to-plasma ratio and QSAR-modelled GABA-A receptor binding affinity for multiple designer BZDs including flualprazolam. s11419-022-00616-y
The primary mortality risk is synergistic respiratory depression when combined with opioids: 83% of postmortem cases involved opioid co-exposure, predominantly fentanylsupported
83% found with opioids (e.g. fentanyl). bkaa070
chemistry2 · 1 ok
Claim in chemistry — inconclusiveinconclusiveworking →
This single-atom modification — the replacement of a hydrogen with fluorine — dramatically alters the compound's pharmacokinetic behaviour, approximately doubling both the volume of distribution and the elimination half-life in rat models.supported
Fluorination increases half-life and Vd, leading to greater exposure and potential toxicity. Flualprazolam shows significant 2-fold increases in volume of distribution; half-life nearly double vs alprazolam. j.taap.2023.116459